Glucagon-like peptide 1 receptor agonist liraglutide impacts immune cell phenotypes in apolipoprotein e deficient mice during progression and regression of pre-established atherosclerosis

Aim: Biologically active macrophages and dendritic cells are the main immune cell subsets which drive atherosclerosis development. Recent evidence suggests liraglutide, the glucagon-like peptide-1 receptor (GLP-1R) agonist, can alter macrophage phenotypes. We hypothesized that liraglutide could limit progression and induce regression of atherosclerosis in vivo via modulation of the inflammatory...